Ravulizumab

證據等級: L5

預測適應症: 10 個

Ravulizumab: From Complement-Mediated Diseases (PNH/aHUS) to Autosomal Recessive Severe Congenital Neutropenia (G6PC3 Deficiency)

One-Sentence Summary

Ravulizumab is a long-acting anti-C5 monoclonal antibody globally approved for complement-mediated diseases such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). TxGNN predicts a possible link to autosomal recessive severe congenital neutropenia due to G6PC3 deficiency, but this prediction is supported by 0 clinical trials and 0 publications, and the underlying mechanistic rationale itself is assessed as weak.

Quick Overview

Item	Content
Original Indication	Not recorded in Taiwan license data (drug not marketed); per embedded rationale, globally approved for complement-mediated diseases (PNH, aHUS)
Predicted New Indication	Autosomal recessive severe congenital neutropenia due to G6PC3 deficiency
TxGNN Prediction Score	99.96%
Evidence Level	L5
US Market Status	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

The formal original_moa field in this evidence pack is a data gap. However, the repurposing rationale attached to the top prediction discloses that ravulizumab is a long-acting anti-C5 monoclonal antibody that inhibits terminal complement activation (formation of the C5b-9 membrane attack complex), and that its approved mechanism targets complement-mediated diseases such as PNH and aHUS.

The predicted new indication — congenital neutropenia due to G6PC3 deficiency — has a fundamentally different pathophysiology: neutropenia in this condition arises from ER stress-induced apoptosis of bone marrow myeloid progenitors, not from complement-driven cell lysis. The evidence pack’s own mechanistic analysis explicitly flags this gap, stating there is “no known direct association” between the G6PC3 pathway and terminal complement activation, and suggests the high TxGNN score may reflect indirect graph proximity around “neutropenia”-related nodes rather than a genuine mechanistic relationship.

This same pattern repeats across ranks 2–10 in this candidate set (cyclic hematopoiesis, primary hyperoxaluria, various congenital neutropenia subtypes, pseudo-von Willebrand disease, platelet release disorders, megaloblastic anemia) — all scored L5 with rationale text noting the absence of a credible complement-mediated mechanism. This suggests the prediction cluster reflects a shared knowledge-graph signal rather than independently validated biology, and should be treated as hypothesis-generating only.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Note: TFDA-equivalent label warnings/contraindications (DG001) are marked as a Blocking data gap in this evidence pack, meaning a formal S1 safety evaluation cannot proceed until this data is obtained.

Conclusion and Next Steps

Decision: Hold

Rationale: This is a pure model-driven (L5) prediction with no supporting clinical trials or literature, and the drug’s own embedded mechanistic rationale explicitly questions the biological plausibility of a complement-C5-to-G6PC3-neutropenia link. Combined with the drug’s non-marketed status in this jurisdiction, there is insufficient basis to advance beyond hypothesis stage.

To proceed, the following is needed:

TFDA (or equivalent) approved label — warnings, contraindications, and DDI data (DG001, blocking)
Confirmed mechanism of action via DrugBank API query (DG002)
Preclinical or translational studies testing whether complement activation contributes to G6PC3-deficient neutropenia pathophysiology
Any case reports or off-label use data of ravulizumab in congenital neutropenia populations
Regulatory pathway assessment, given zero existing local market authorization
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.